Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price ...

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

【ビジネスワイヤ】米女性化粧品ブランドのメアリー・ケイは、オハイオ州コロンバスで開催の高校生向けグローバルＳＴＥＭコンペティション「リジェネロン国際学生科学技術フェア（Ｒｅｇｅｎｅｒｏｎ・ＩＳＥＦ）」に特別賞授与団体として参加したことを発表した。同フェアは、６０カ国以上から約２０００人が参加し、総額９００万ドルを超える賞金や奨学金が与えられるとともに、ＳＴＥ ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

This was the stock's second consecutive day of losses.

DNA data saved: 23andMe co-founder Anne Wojcicki has bid $305 million through a nonprofit to acquire her bankrupt company, ...